Apotex's FDA approval for ANDA 077615 on July 29 signals a strategic push to capitalize on market competition, positioning the company to capture significant share immediately post-patent expiration and expand its generic revenue base.
Apotex's FDA approval for ANDA 077615 on July 29 signals a strategic push to capitalize on market competition, positioning the company to capture significant share immediately post-patent expiration and expand its generic revenue base.